Kellen Scott 4

What Happened Kellen Scott, CFO and Secretary of DiaMedica Therapeutics Inc. (DMAC), was granted a derivative award for 162,000 shares reported on Form 4. The grant was reported as an acquisition at $0.00 per share (transaction code A), i.e., an award of equity-linked interests rather than an open-market purchase or sale. The filing shows the award amount but does not report an immediate cash value because the shares are subject to vesting.

Key Details

• Transaction date: 2026-06-01; Form 4 filed 2026-06-03 (appears timely).
• Grant: 162,000 shares, acquisition price reported as $0.00 (derivative award).
• Vesting (footnote): 25% vests on the one-year anniversary of the grant; the remaining 75% vests in twelve equal quarterly installments (implying a 4-year total schedule).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• No indication of a 10b5-1 plan, cashless exercise, tax-withholding sale, or other sale/transfer in this filing.

Context This filing documents a compensation-related equity award (common for executives) rather than a market purchase or sale. Such awards typically vest over time to align the executive’s incentives with company performance and retention; they do not represent immediate proceeds to the insider unless and until vested (and possibly sold).